Form 4: Tarsus Director Settles RSUs, Adjusts Holdings

Tarsus Pharmaceuticals director Scott W. Morrison settled vested Restricted Stock Units and adjusted his common stock holdings, resulting in an indirect beneficial ownership of 6,016 shares.

Summary

• Director Scott W. Morrison reported transactions involving Tarsus Pharmaceuticals, Inc. common stock on September 15, 2025.
• Morrison acquired 1,334 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• Concurrently, 4,684 shares of common stock were disposed of.
• Following these transactions, Morrison's indirect beneficial ownership stands at 6,016 shares, held through the Morrison-Minton Family 2004 Trust.
• The RSUs vested in three equal annual installments on September 15th of 2023, 2024, and 2025, contingent on continuous service.

Sentiment

Score: 5

Explanation: A routine insider transaction involving RSU vesting and subsequent share adjustment, common for executive compensation, which typically has a neutral impact on sentiment.

Positives

• The vesting and settlement of 1,334 Restricted Stock Units indicate continued service and compensation for Director Scott W. Morrison.

Negatives

• A disposition of 4,684 shares of common stock occurred, which represents a net reduction in the director's direct holdings after accounting for the RSU settlement.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide information directly related to broader industry trends or competitor performance.

Related Party Transactions

• Indirect beneficial ownership of 6,016 common stock shares is held through the Morrison-Minton Family 2004 Trust, where the reporting person, Scott W. Morrison, is a trustee and a sole beneficiary along with his spouse.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation-related transaction for a director.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction involving the settlement of vested Restricted Stock Units and a subsequent adjustment of common stock holdings by a director. This type of transaction is common for executive compensation and does not provide new fundamental information to warrant a change in investment recommendation.

Keywords

Tarsus Pharmaceuticals, TARS, Scott W. Morrison, Form 4, SEC filing, insider transaction, RSU, Restricted Stock Units, common stock, director, beneficial ownership